Enlivex Therapeutics Ltd.: Difference between revisions
>Nick Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. == References and notes == Ca..." |
(No difference)
|
Latest revision as of 05:58, 26 August 2022
Summary[1] edit edit source
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
References and notes edit edit source
- ↑ Source: Yahoo Finance.